Cuppone et al. Journal of Experimental & Clinical Cancer Research 2011, 30:54 http://www.jeccr.com/content/30/1/54 Table 1 Trials’ Characteristics Prior chemotherapy lines for metastatic disease Mostly 1-2 Authors Pts Miller et 462 al Gray et 722 al Miles et 736 al Dieras et 622 al 615 Bruwski 684 et al 0 0 0 1 Arms Cap (2,500 mg/m2/day, days 1-14) 49.7% Cap (2,500 mg/m2/day, days 1-14) + Beva (15 mg/kg) wPac (90 mg/m2 day 1, 8 and 15) 45.7% wPac (90 mg/m2 day 1, 8 and 15)+ Beva (10 mg/kg) Doc (100 mg/m2) 35.0% Doc (100 mg/m2)+ Beva 7.5 (7.5 mg/ 33.4% kg) Doc (100 mg/m2)+ Beva 15 (15 mg/ kg) A/T A/T + Beva (15 mg/kg) Cap (2,000 mg/m2/day, days 1-14) Cap (2,000 mg/m2/day, days 1-14) + Beva (15 mg/kg) Chemo Chemo + Beva > 3 sites 54.5% 27.8% No adjuvant Chemo NR 34.2% 54.8% 54.9% 45.2% 43.9% Visceral site 78.7% 62.2% NR 70.4% 68.8% Hormonal Receptors Negative (RN) NR 36.7% 17.1% 17.1% 24.0% 23.6% 27.7% Page 4 of 9 Prior taxanes (T) 100% Prior Anthra (A) 100% 14.9% 37.2% 14.9% 16.2% 15.0% 39.5% 53.7% 53.5% 29.9% 62.9% 45.3% NR 73.1% NR NR Outcome Hazard ratio and 95% CI Group by Treatment Line First First First First First First Second Second Second First First First First First First Second Second Study name Gray JCO 2009 Dieras [A/T] ECCO 2009 Dieras [Cap] ECCO 2009 Miles [Beva15] JCO 2010 Miles [Beva7.5] JCO 2010 Bruwsky SABCS 2009 Miller JCO 2005 Dieras [Cap] ECCO 2009 Gray JCO 2009 Dieras [A/T] ECCO 2009 Miles [Beva15] JCO 2010 Miles [Beva7.5] JCO 2010 Bruwsky SABCS 2009 PFS PFS PFS PFS PFS PFS PFS OS OS OS OS OS OS Pt: patients; RN: receptor negative; T: taxanes (3-weekly Docetaxel or protein-bound paclitaxel); Anthra (A): anthracyclines (various regimens: AC, EC, FAC, FEC); Cap: capecitabine; Beva: Bevacizumab; NR: not reported; wPac: weekly paclitaxel; Doc: docetaxel; Chemo: various chemotherapies. 0.5 1 2 Favours BEVA Favours Control Figure 2 Combined Results - Efficacy Outcomes (PFS, OS). CI: confidence intervals; A: anthracyclines; T: taxanes; Cap: capecitabine; Beva: bevacizumab; PFS: progression free survival; OS: overall survival.